Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients

被引:11
|
作者
Lloyd-Jones, Donald M.
Huffman, Mark D.
Karmali, Kunal N.
Sanghavi, Darshak M.
Wright, Janet S.
Pelser, Colleen
Gulati, Martha
Masoudi, Frederick A.
Goff, David C., Jr.
机构
关键词
AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke; ASSOCIATION TASK-FORCE; ADULT TREATMENT PANEL; OUTCOME INCIDENCE; NATIONAL-HEALTH; MULTIFACTORIAL INTERVENTION; MYOCARDIAL-INFARCTION; STATIN ELIGIBILITY; LOWERING TREATMENT; AMERICAN-COLLEGE; UNITED-STATES;
D O I
10.1016/j.jacc.2016.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk"by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
引用
收藏
页码:1617 / 1636
页数:20
相关论文
共 50 条
  • [21] Estimating Cardiovascular and Limb Benefits of Combined Contemporary Risk Reduction Therapies in Patients with Symptomatic Peripheral Artery Disease: An Analysis of Randomized Controlled Trials
    Hussain, Mohamad A.
    Dey, Tanujit
    Lipsitz, Stuart R.
    Bhatt, Deepak L.
    Verma, Subodh
    Eikelboom, John W.
    Bonaca, Marc P.
    Belkin, Michael
    Ozaki, C. Keith
    Al-Omran, Mohammed
    CIRCULATION, 2021, 144
  • [22] Effects of the Affordable Care Act's enhancement of Medicare benefits on preventive services utilization among older adults in the US
    Toseef, Mohammad Usama
    Jensen, Gail A.
    Tarraf, Wassim
    PREVENTIVE MEDICINE, 2020, 138
  • [23] LONGITUDINAL PATTERNS OF ANTIDIABETES MEDICATION PRESCRIPTION AMONG PRIVATELY INSURED MEDICARE PATIENTS
    Bae, J. P.
    Peng, X.
    Jiang, D.
    Zagar, A.
    VALUE IN HEALTH, 2014, 17 (03) : A263 - A263
  • [24] Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks
    Alroughani, Raed
    Altintas, Ayse
    Al Jumah, Mohammed
    Sahraian, Mohammadali
    Alsharoqi, Issa
    AlTahan, Abdurahman
    Daif, Abdulkader
    Dahdaleh, Maurice
    Deleu, Dirk
    Fernandez, Oscar
    Grigoriadis, Nikolaos
    Inshasi, Jihad
    Karabudak, Rana
    Taha, Karim
    Totolyan, Natalia
    Yamout, Bassem I.
    Zakaria, Magd
    Bohlega, Saeed
    MULTIPLE SCLEROSIS INTERNATIONAL, 2016, 2016
  • [25] The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
    Fujii, Yoshitaka
    CURRENT DRUG SAFETY, 2008, 3 (01) : 27 - 34
  • [26] EVALUATION OF THE BURDEN OF GENERAL CARDIOVASCULAR DISEASE AMONG UNITED STATES MEDICARE PATIENTS
    Xie, L.
    Wang, L.
    Li, L.
    Wang, Y.
    Du, J.
    Baser, O.
    VALUE IN HEALTH, 2014, 17 (03) : A111 - A111
  • [27] Temporal Trends in Use of Complementary Therapies Among Patients With Cardiovascular Disorders
    Prasad, Kavita
    Prasad, Abhiram
    George, Merit
    Sandhu, Gurpreet S.
    Inojosa, Jose R. Medina
    Bhagra, Anjali
    Mahpatra, Saswati M.
    Petterson, Tanya M.
    Lackore, Kandace A.
    Croghan, Ivana T.
    Bauer, Brent A.
    Wahner-Roedler, Dielind L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 167 : 118 - 124
  • [28] Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
    Graham, David J.
    Reichman, Marsha E.
    Wernecke, Michael
    Zhang, Rongmei
    Southworth, Mary Ross
    Levenson, Mark
    Sheu, Ting-Chang
    Mott, Katrina
    Goulding, Margie R.
    Houstoun, Monika
    MaCurdy, Thomas E.
    Worrall, Chris
    Kelman, Jeffrey A.
    CIRCULATION, 2015, 131 (02) : 157 - 164
  • [29] The risks and benefits of thromboprophylaxis (TP) among hospitalized medically ill cancer patients
    Carrier, M.
    Wu, C.
    Peterson, E.
    de Wit, C.
    Ma, M.
    Tien, J.
    Polley, G.
    Lee, A. Y.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 208 - 208
  • [30] Views and approaches toward risks and benefits among doctors who become patients
    Klitzman, Robert
    PATIENT EDUCATION AND COUNSELING, 2006, 64 (1-3) : 61 - 68